Achaogen is a late-stage biopharmaceutical company committed to the development of innovative antibacterial treatments against MDR, gram-negative infections.
We’re wrapping up a great #IDWeek2018 meeting building stronger connections with this incredible community. We move forward energized and mutually committed to tackling #AntibioticResistance
Our posters 1964 and 2060 at #IDWeek2018 show what we've learned in our efforts to help address certain gram-negative infections. Come by and see us today!
#IDWeek2018 Today: Come by our poster sessions (1400, 1345) or booth 909 to learn about the study results for certain gram-negative infections. Schedule: bit.ly/2O4XbzJ
#IDWeek2018 Preview: Come by our poster sessions (1348, 1400, 1345, 1964, 2060) to learn about our efforts to help address certain gram-negative infections. Schedule: bit.ly/2O4XbzJ
Attending #IDWeek2018? Then please join us to hear about the microbiological outcomes in adult patients with complicated urinary tract infections, #cUTI, from our Phase 3 EPIC study.
We’re at #IDWeek2018 with the #InfectiousDisease community to help address the significant and growing challenge of difficult-to-treat infections and #AntibioticResistance in hospital and outpatient settings. Come see us at booth 909.
We’ve got a lot planned for #IDWeek2018, we’ll be sharing one oral abstract and five poster presentations focused on in vitro, microbiological and clinical data. For more details go to: bit.ly/2O4XbzJ
We’ll be at #IDWeek2018 to share our work on treating adults with complicated urinary tract infections. To learn about our efforts to help address #cUTIs, visit us at booth 909. Details of oral & poster sessions can be found here: bit.ly/2O4XbzJ
As other biopharma companies step away from antibiotics, we remain committed to the space because the growth of resistance to antibiotics is driving a very real urgent medical need. #IDWeek2018#AntibioticResistance#InfectiousDisease
Pediatricians in St. Louis are changing the way they talk about treating premature infants in an effort to curb unnecessary exposure to #antibiotics. bit.ly/2MIb6Ku via @stlpublicradio
"One of the must read papers of the year" from CDDEP Director Ramanan Laxminarayan and colleagues from Australia. Sanitation, clean water, and good governance are necessary to reduce global antimicrobial resistance. ow.ly/Ffl050ipzZt
Recently English hospitals have seen a sharp increase in the use of a "last hope" #antibiotic called #Colistin. Experts blame a rise in the most dangerous types of #superbugs, and warn it's only a matter of time before Colistin stops working too. bit.ly/2mu9umQ